Multiple government agencies are working in tandem to address the massive opioid epidemic plaguing the United States. While some policymakers have called for more oversight of FDA's approval of opioids, such as providing Congress the authority to review drug approval decisions by the agency made against the recommendations of advisory panels, other stakeholders have urged FDA to take a more aggressive approach in requiring abuse-deterrent properties for new drug applications. Ambiguity in the law could provide FDA the authority to...